Novo Nordisk: Saxenda Approved In Europe To Treat Obesity

(RTTNews) - Novo Nordisk (NVO) on Monday said the European Commission has granted marketing authorisation for Saxenda for the treatment of obesity.

The authorisation covers all 28 European Union member states. Novo Nordisk said it expects to launch Saxenda in several European markets starting in 2015.

Saxenda (liraglutide 3 mg) is the brand name of liraglutide 3 mg, the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity approved in Europe.

Saxenda is indicated in the EU as an adjunct to a reduced-calorie diet and increased physical activity in obese and overweight adult patients in the presence of at least one weight-related comorbidity such as dysglycaemia, hypertension, dyslipidaemia or obstructive sleep apnoea.

Saxenda was approved in the U.S. in December 2014 and in Canada in February 2015, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity or who are overweight with at least one weight-related comorbidity.